 |
 Video: What is a Stock Split?
|
|
|
| Gritstone bio is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. Co. discovers, develops, manufactures, and delivers cancer and infectious disease immunotherapy candidates by utilizing both of its vaccine vectors, self-amplifying mRNA and chimpanzee adenovirus. Co.'s oncology programs in clinical stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. Co.'s programs in clinical stage development are: CORAL, a second generation COVID-19 vaccine program and an HIV therapeutic/cure vaccine candidate that Co. is collaborating on with Gilead Sciences, Inc. According to our Gritstone bio stock split history records, Gritstone bio has had 0 splits. | |
|
Gritstone bio (GRTS) has 0 splits in our Gritstone bio stock split history database.
Looking at the Gritstone bio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Gritstone bio shares, starting with a $10,000 purchase of GRTS, presented on a split-history-adjusted basis factoring in the complete Gritstone bio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/01/2018 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$13.45 |
|
| End price/share: |
$0.96 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-92.86% |
|
| Average Annual Total Return: |
-37.63% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$713.76 |
|
| Years: |
5.59 |
|
|
|
|
|
